Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China. — ALK POSITIVE

Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China.

Clinical TrialsKirk SmithMay 17, 2022alectinib, anaplastic lymphoma kinase, non-small-cell lung cancer, real-world study